TherapeuticsMD Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2010
Revenue	1.3	69.96	2.57	64.87	49.65	Upgrade
Revenue Growth (YoY)	-98.14%	2619.12%	-96.03%	30.67%	208.38%	Upgrade
Cost of Revenue	0	1.4	1.4	15.98	6.34	Upgrade
Gross Profit	1.3	68.57	1.17	48.9	43.31	Upgrade
Selling, General & Admin	8.9	56.71	80.75	194.01	174.73	Upgrade
Research & Development	0	0	0	10.43	19.79	Upgrade
Other Operating Expenses	0.92	10.67	0	0	0	Upgrade
Operating Expenses	9.83	67.38	80.75	204.44	194.52	Upgrade
Operating Income	-8.52	1.19	-79.58	-155.54	-151.21	Upgrade
Interest Expense / Income	0	0	0	28.58	17.38	Upgrade
Other Expense / Income	1.8	-110.81	92.84	-0.6	7.56	Upgrade
Pretax Income	-10.32	112	-172.42	-183.52	-176.15	Upgrade
Income Tax	-0.04	0	0	0	0	Upgrade
Net Income	-10.28	112	-172.42	-183.52	-176.15	Upgrade
Shares Outstanding (Basic)	10	9	8	6	5	Upgrade
Shares Outstanding (Diluted)	10	9	8	6	5	Upgrade
Shares Change	11.48%	17.66%	44.39%	11.89%	9.48%	Upgrade
EPS (Basic)	-0.98	12.41	-21.66	-33.50	-36.00	Upgrade
EPS (Diluted)	-0.98	11.96	-21.66	-33.50	-36.00	Upgrade
Free Cash Flow	-48.14	-4.08	-142.73	-159.68	-168.17	Upgrade
Free Cash Flow Per Share	-4.61	-0.45	-17.93	-28.96	-34.13	Upgrade
Gross Margin	100.00%	98.00%	45.51%	75.37%	87.24%	Upgrade
Operating Margin	-654.61%	1.70%	-3092.77%	-239.77%	-304.56%	Upgrade
Profit Margin	-789.40%	160.08%	-6700.93%	-282.90%	-354.79%	Upgrade
Free Cash Flow Margin	-3697.47%	-5.83%	-5547.10%	-246.14%	-338.73%	Upgrade
EBITDA	-9.4	113.19	-171.68	-150.88	-157.37	Upgrade
EBITDA Margin	-721.89%	161.79%	-6672.33%	-232.57%	-316.98%	Upgrade
Depreciation & Amortization	0.92	1.19	0.74	4.07	1.39	Upgrade
EBIT	-10.32	112	-172.42	-154.94	-158.76	Upgrade
EBIT Margin	-792.70%	160.08%	-6700.93%	-238.84%	-319.78%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).